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It is largely unknown how invading autoreactive T cells initiate the pathogenic process 
inside the diseased organ in organ-specific autoimmune diseases. In experimental 
autoimmune uveitis (EAU) induced by uveitogenic, interphotoreceptor retinoid-binding 
protein (IRBP)-specific T cells (tEAU) in mice, we have previously reported that high mobility 
group box 1 (HMGB1) released as a consequence of the direct interaction between 
IRBP-specific T cells and retinal parenchymal cells is an early and critical mediator in 
induction of intraocular inflammation. Our present study explored the roles of HMGB1 
in intraocular inflammation, focusing on its role in recruiting inflammatory cells into the 
eye. Our results showed that supernatants from retinal explants either stimulated with 
HMGB1 or cocultured with IRBP-specific T cells attracted leukocytes. Notably, HMGB1 
antagonists blocked supernatant-induced chemoattraction when present from the start 
of coculture, but not when added to the culture supernatants after coculture, indicating 
that molecules released by HMGB1-treated retinal cells are chemoattractive. Moreover, 
CXCL12 levels in the coculture supernatants were dependent on HMGB1, since they were 
increased in the cocultures and reduced when HMGB1 antagonists were added at the 
beginning of the coculture. When either anti-CXCL12 Ab was added to the supernatants 
after coculture or the responding lymphocytes were pretreated with Ab against CXCL12 
specific receptor, CXCR4, chemoattraction by the coculture supernatants was decreased. 
Finally, induction of tEAU was significantly inhibited by a CXCR4 antagonist, AMD3100, 
at the time of autoreactive T cell transfer. Our study demonstrates that, at a very early 
stage of intraocular inflammation initiated by uveitogenic autoreactive T cells, synergism 
between HMGB1 and CXCL12 is crucial for the infiltration of inflammatory cells.
Keywords: autoimmune disease, uveitis, immune regulation, autoreactive T cells, damage-associated molecular 
patterns, hMgB1, cXcl12, cXcr4
Abbreviations: EAU, experimental autoimmune uveitis; HMGB1, high mobility group box 1; IRBP, interphotoreceptor 
retinoid-binding protein; RAGE, receptor for advanced glycation end products; tEAU, activated IRBP-specific T cell-induced 
EAU, TREM-1, triggering receptor expressed on myeloid cells-1.
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inTrODUcTiOn
Autoimmune uveitis is a group of potentially visually disabling 
intraocular inflammatory diseases that arise without a known 
infectious trigger. Although the etiology remains unclear, it is 
generally believed that a T cell-mediated immune response to 
unique ocular proteins underlies the pathogenesis of the disease 
and this is supported by the observation that adoptive transfer 
of uveitogenic autoreactive T cells into susceptible, syngeneic 
rodents induces experimental autoimmune uveitis (tEAU) 
(1–4). Studies in rodent models of experimental autoimmune 
uveitis (EAU) induced by immunization of a well-characterized 
uveitogenic autoantigen, interphotoreceptor retinoid-binding 
protein (IRBP), have shown that activation of autoreactive 
T  cells is a key pathogenic event linked to disease induction, 
progression, and recurrence (2, 4–7). While a great deal of 
information is available about the development and activation 
of autoimmune T cells in the periphery in EAU, the mecha-
nism by which the low frequency of infiltrating uveitogenic 
T cells triggers and maintains the intraocular inflammatory 
cascade is unknown. The tEAU model, which, in contrast to 
the antigen-immunization EAU model, is induced without 
injecting microbial products and resembles human chronic 
uveitis, allows us to study the behavior of infiltrating effector 
T cells inside the eye.
Using this tEAU model, we have previously demonstrated 
that, once peripheral activated IRBP-specific T cells enter 
the eye, they interact with parenchymal cells, resulting in the 
production of high mobility group box 1 (HMGB1) by these 
cells (8). Released HMGB1 in the eye plays an early and critical 
role in IRBP-specific T cell-induced intraocular inflammation, 
because neutralization or blockade of HMGB1 using antagonists 
reduces ocular inflammation and suppresses uveitogenic T cell 
function, such as IRBP-specific T cell proliferation and cytokine 
production (8). We also found that HMGB1 is actively secreted 
within the eye within 24 h after IRBP-specific T cell transfer as 
a consequence of direct cell–cell contact between infiltrating 
IRBP-specific T cells and viable retinal cells (8), which is medi-
ated by the Fas/FasL interaction (9). However, the mechanisms 
by which released HMGB1 induces intraocular inflammatory 
cascade are unknown. In the present study, we aimed to define 
the role of HMGB1 in inflammatory cell infiltration into the eye, 
one of the major pathogenic events initiated by the few IRBP-
specific T cells that enter the eye.
High mobility group box 1 is one of the most important dam-
age-associated molecular pattern molecules. Although itself is 
only a weak inflammatory mediator, its interaction with receptor 
for advanced glycation end products (RAGE) (10) or TLRs (11) 
leads to increased production and release of cytokines and other 
inflammatory molecules. HMGB1 also binds to nucleosomes, 
RNA and DNA, lipopolysaccharide, thrombospondin, trigger-
ing receptor expressed on myeloid cells-1, CD24, and CXCL12, 
promoting inflammatory responses (10). Three isoforms of 
HMGB1 have been discovered, with disulfide HMGB1 inducing 
cytokine production via TLR4, fully reduced HMGB1 promoting 
chemotaxis by binding CXCL12 for stimulation via CXCR4, and 
the fully oxidized HMGB1 being inactive (12).
We therefore investigated whether the interaction of autoreac-
tive T cells and retinal cells leads to cooperation of HMGB1 and 
CXCL12 in promoting leukocyte migration in vitro and in vivo, 
and whether blocking HMGB1/CXCL12 complex inhibits its che-
moattractive function, resulting in the reduction of intraocular 
inflammation.
MaTerials anD MeThODs
animals and reagents
Eight- to ten-week-old female C57BL/6J (B6) mice, purchased 
from the Jackson Laboratory (Bar Harbor, ME, USA), were 
housed and maintained in the animal facilities of the University 
of Louisville (KY, USA). All animal studies conformed to the 
Association for Research in Vision and Ophthalmology state-
ment about the use of animals in ophthalmic and vision research. 
The protocol (#14052) was approved by the Institutional Animal 
Care and Use Committee of the University of Louisville.
All T cells were cultured in complete medium [RPMI 1640 
medium (Mediatech, Manassas, VA, USA) supplemented with 
10% fetal calf serum (Hyclone, Logan, UT, USA), 5 ×  10−5  M 
2-mercapatoethanol, and 100 µg/ml of penicillin/streptomycin]. 
The human IRBP peptide 1–20 (GPTHLFQPSLVLDMAKVLLD) 
was synthesized by Sigma-Aldrich (St. Louis, MO, USA). The 
fully reduced HMGB1 (Cat#HM-115) was purchased from 
HMGBiotech (Milano, Italy) and chicken anti-HMGB1 poly-
clonal antibody (Cat#326052233) from Shino-Test Corporation 
(Kanagawa, Japan).
induction of teaU
The method used to induce tEAU has been reported previously 
(4). Briefly, T cells from mice immunized 12 days previously with 
peptide IRBP1–20 were purified from draining lymph nodes and 
spleen cells by passage through a nylon wool column (Polysciences, 
Warrington, PA, USA), then 1 × 107 cells in 2 ml of RPMI 1640 
medium were added to each well of a six-well plate (Costar, 
Corning, NY, USA) and stimulated with 20  µg/ml of IRBP1–20 
in the presence of 1 ×  107-irradiated syngeneic spleen cells as 
antigen-presenting cells (APCs). After 2  days, activated lymph 
blasts were isolated by gradient centrifugation on Lymphoprep 
(Sigma-Aldrich) and injected intraperitoneally (i.p.) in 0.2 ml of 
PBS into naive B6 recipients (5 × 106 cells/mouse). The clinical 
course of the disease was assessed by indirect fundoscopy once or 
twice a week and graded as described previously (13).
Pathological examination
Inflammation of the eye was confirmed by histopathology. Whole 
eyes were collected, immersed for 1 h in 4% phosphate-buffered 
glutaraldehyde, and transferred to 10% phosphate-buffered for-
maldehyde until processed. The fixed and dehydrated tissue was 
embedded in methacrylate, and 5 µm sections were cut through 
the pupillary-optic nerve plane and stained with hematoxylin 
and eosin. Presence or absence of disease was evaluated blind 
by examining six sections cut at different levels for each eye. 
Severity of EAU was scored on a scale of 0 (no disease) to 4 
(maximum disease) in half-point increments based on the 
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presence of inflammatory cell infiltration of the iris, ciliary body, 
anterior chamber (AC), and retina (4).
isolation of retinal explants and coculture 
with activated irBP1–20-specific T cells or 
hMgB1
Eyes were collected from B6 mice and neural retinas isolated and 
used as retinal explants as described previously (8, 9). Retinal 
explants were placed with the inner membrane facing up in a 
24-well plate and cultured in 500  µl of DMEM/F12 medium 
(Mediatech Inc., Manassas, VA, USA) containing 0.1% fetal calf 
serum, then either HMGB1 (0.1 or 1 µg/ml) or 5 × 104-activated 
T cells, prepared from IRBP1–20-immunized mice at day 11–14 
postinjection as described above, was added and the cells incu-
bated at 37°C with 5% CO2 for 6 h, then CXCL12 and HMGB1 
levels in the supernatants were measured by ELISA, as described 
below. In inhibitor studies, retinal explants were cocultured with 
activated IRBP1–20-specific T cells in the presence or absence of anti-
HMGB1 mAb (IBL international GmbH, Toronto, ON, Canada), 
anti-RAGE mAb (R&D, Minneapolis, MN, USA), or glycyrrhizin 
(Calbiochem) for 6  h, then the supernatants were collected for 
ELISA or chemotactic assays.
intraocular inoculations
B6 mice were anesthetized by i.p. injection of ketamine (80 mg/kg, 
JHP Pharmaceuticals, Rochester, MI, USA) and xylazine (10 mg/
kg, Akorn, Decatur, IL, USA). One drop of 0.5% tropicamide and 
1.25% phenylephrine hydrochloride ophthalmic solutions was 
applied topically on the eye before injection. Under a dissecting 
microscope, 1 µl of 1 µg anti-HMGB1 Ab was injected into the 
AC, one eye with a microliter syringe and a 33-gauge needle 
(Hamilton, Reno, NV, USA).
intraocular Fluid collection
The removed eyeball was immersed in 200 µl of PBS and cut in 
two, then the cornea, sclera, and lens were discarded and the rest 
of the tissue cut into small pieces and the suspension containing 
the aqueous humor, vitreous fluid, and fine pieces of tissue centri-
fuged at 500 g for 5 min at 4°C, then the supernatant (intraocular 
fluid) was immediately stored in a −80°C freezer until use. Half 
(about 100 µl) of each collection from one eyeball was used for 
CXCL12 measurement by ELISA.
isolation of eye-infiltrating cells
Eyes were collected after PBS perfusion, and a cell suspension 
was prepared by digestion for 10 min at 37°C with collagenase 
(1  mg/ml) and DNase (100  µg/ml) in RPMI 1640 containing 
10% FCS. The cells were washed, re-suspended in staining buffer 
(PBS containing 3% FCS and 0.1% sodium azide), and stained 
with fluorescent mAbs to identify inflammatory cells by flow 
cytometry.
elisa for hMgB1 and cXcl12
Culture supernatants from retina explants or intraocular fluid, 
prepared as described above, were added to wells pre-coated with 
HMGB1 (Abcam, Cambridge, MA, USA) or CXCL12 capture Abs 
(R&D System, Minneapolis, MN, USA) and levels of HMGB1 or 
CXCL12 measured following the manufacturer’s instruction.
immunohistochemistry for cXcl12 and 
cXcr4
To detect expression of CXCL12 and CXCR4 on the retina, 
paraffin-embedded tissue slides were deparaffinized and rehy-
drated with xylene and 100, 95, and 80% ethanol. After antigen 
retrieval in a citrate-buffered solution in a boiling water bath, the 
tissue was blocked by incubation with 3% BSA for 1 h at room 
temperature, then the slides were double-stained by overnight 
incubation at 4°C with phycoerythrin (PE)-labeled anti-CXCL12 
Ab (R&D) or anti-CXCR4 Ab (R&D) and fluorescein isothiocy-
anate (FITC)-labeled anti-glutamine synthetase (GS) Ab (Sigma, 
St. Louis, MO, USA) or anti-Iba-1 Ab (Abcam, Cambridge, MA, 
USA), then the nuclei were counterstained with DAPI (Sigma) 
and the slides examined by fluorescence microscopy.
In Vivo Treatment with aMD3100, a 
specific inhibitor of cXcr4
We followed the protocol for AMD3100 treatment previously 
described by Matthys et al. (14). The mice were anesthetized by 
i.p. injection of ketamine (80 mg/kg) and xylazine (10 mg/kg), and 
a number 2002 Alzet osmotic minipump (Alza, Palo Alto, CA, 
USA) was implanted dorsolaterally under the skin. The pumps 
were filled with 5 mg of AMD3100 in 90 µl of PBS, which was 
delivered at a rate of 0.25 µl/h (357 µg/day) for 14 days. Groups 
of mice implanted with pumps containing only PBS were also 
included. Other untreated mice were anesthetized like the treated 
ones but were not implanted with pumps.
assays for irBP-specific T cell 
Proliferation and cytokine Production
Nylon wool-enriched T cells prepared at 15 days after transfer of 
IRBP1–20-specific T cells into B6 mice were seeded at 4 × 105 cells/
well in 96-well plates and cultured at 37°C for 60 h in 200 µl of 
complete medium with or without the indicated concentration 
of IRBP1–20 in the presence of irradiated syngeneic spleen APCs 
(1  ×  105), and [3H]thymidine incorporation during the last 
8  h assessed using a microplate scintillation counter (Packard 
Instruments). The proliferative response was expressed as the 
mean cpm ± SD for triplicate samples or the proliferative stimu-
lus index, calculated as the mean cpm for antigen-stimulated 
cultures/mean cpm for unstimulated controls ratio, for triplicate 
samples. To measure cytokine production by responder T cells, 
supernatants were collected 48  h after T  cell stimulation and 
assayed for IFN-γ, IL-17, and IL-10 using ELISA kits (R&D).
chemotaxis assay
Splenocytes (3 × 105 cells/well) from naïve B6 mice that had either 
been left untreated or been incubated for 30 min with 50 µg/ml 
of anti-CXCR4 Ab, then washed, were added to the upper wells 
of 24-well Transwell micro-chemotaxis devices (5 µm pore size; 
Costar) and either medium with or without HMGB1 or CCL2 
or supernatants from cell cultures or cocultures was added to the 
lower wells. In inhibitor studies, the inhibitor was added either at 
FigUre 1 | high mobility group box 1 (hMgB1) release as a consequence of the interaction of uveitogenic T cells and retinal cells is critical for the 
production of chemotactic molecules by retinal cells. (a) Retinal explants from naïve B6 mice or activated interphotoreceptor retinoid-binding protein 
(IRBP)-specific T cells were cultured alone or together for 6 h, then culture supernatants were assayed for HMGB1 by ELISA. (B,c) Chemotactic index of medium or 
the supernatant from the T cells or retinal explants or the supernatant from the cocultures either alone or with anti-HMGB1 Ab (8 µg/ml), glycyrrhizin (200 µg/ml), or 
anti-receptor for advanced glycation end products (RAGE) Ab (30 µg/ml) added at the end of the coculture (B), or at the beginning of the coculture (c). The results 
are representative of those for three experiments. **p < 0.01 compared to medium alone, #p < 0.05 and ##p < 0.01 compared to the coculture of retinal explants 
and IRBP-specific T cells in one-way ANOVA.
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the beginning of cocultures or to the coculture supernatant at the 
end of coculture. After 2 h, cells that had migrated to the lower 
wells were collected, counted, stained with antibodies against CD3 
for T cells, CD11b for macrophages, or Gr-1 for granulocytes, and 
examined by flow cytometry. The chemotactic index was calculated 
as the ratio of the number of migrated cells in chemoattractant-
containing wells divided by the number of migrated cells in 
medium-containing wells. All assays were performed in triplicate.
statistical analysis
Experiments were repeated at least three times. An unpaired 
Student’s t-test for two sets of data, one-way or two-way ANOVA 
for three or more means, or the Mann–Whitney U test for the 
pathological score of uveitis was used for statistical analysis. 
A p value < 0.05 was considered significant.
resUlTs
hMgB1, released as a consequence of 
the interaction between Uveitogenic T cells 
and retinal cells, is critical for the 
Production of chemotactic Molecules 
by retinal cells
To examine the chemotactic ability of HMGB1 released after the 
interaction between uveitogenic T cells and retinal cells, we col-
lected the supernatants from cocultures of activated IRBP-specific 
T cells and retinal explants for an in  vitro chemoattractant 
migration assay. In this assay, splenocytes from naïve B6 mice 
were added to the top well of a chemotaxis chamber and coculture 
supernatants alone or together with 8 µg/ml of anti-HMGB1 mAb, 
200 µg/ml of glycyrrhizin (an HMGB1 inhibitor), or 30 µg/ml of 
anti-RAGE mAb was added to the lower well, then the number of 
cells that migrated to the lower well after 2 h was counted by flow 
cytometry. As shown in Figure 1A, HMGB1 was released into 
the medium of the cocultures, as shown previously in Ref. (8). 
These supernatants were chemoattractive for splenocytes, both 
alone and after addition of anti-HMGB1 Ab, glycyrrhizin, or anti-
RAGE Ab (Figure 1B). However, when the same concentration 
of anti-HMGB1 Ab, glycyrrhizin, or anti-RAGE Ab was added at 
the beginning of the coculture of retinal explants and activated 
IRBP-specific T cells, the supernatants from these cocultures no 
longer attracted splenocytes (Figure 1C), showing that HMGB1 
and RAGE are involved in the release of a chemotactic molecule 
produced during the interaction between T cells and retinal cells.
hMgB1 alone cannot recruit 
inflammatory cells, Whereas supernatants 
from retinal explants stimulated with 
hMgB1 Do recruit inflammatory cells
High mobility group box 1 alone is reported to have no chemo-
tactic activity to leukocytes (15, 16), and we confirmed this in 
Figure  2A, in which no migration of splenocytes from naïve 
FigUre 2 | high mobility group box 1 (hMgB1) alone cannot induce splenocyte migration, whereas supernatants collected from retinal explants 
stimulated with hMgB1 can. Splenocytes from naïve B6 mice were added to the top well of the chemotaxis chamber. (a) The chemotactic index of different 
concentrations of HMGB1 or 10 nM CCL21. (B) The chemotactic index of the medium only or supernatant from cultures of retinal explants incubated for 6 h with 
medium or 1 µg/ml of HMGB1 in the presence or absence of 1 µg/ml of anti-HMGB1Ab. **p < 0.01 compared to medium alone in one-way ANOVA.
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B6 mice was seen in the medium containing 0, 0.1, or 1 µg/ml 
of reduced form of HMGB1, contrast to that of the medium 
containing 10  nM CCL12, a chemoattractant for lymphocytes. 
However, as shown in Figure  2B, supernatants collected from 
retinal explants stimulated with 1 µg/ml of HMGB1 did attract 
splenocytes, while supernatants from the same cells incubated 
with HMGB1 and 1 µg/ml of anti-HMGB1 Ab did not. The results 
show that molecules released from HMGB1-stimulated retinal 
cells attract immune cells.
cXcl12 is the Molecule induced by 
hMgB1 That attracts immune cells
The HMGB1-induced recruitment of inflammatory cells depends 
on CXCL12, and HMGB1 and CXCL12 form a heterocomplex 
that binds exclusively to CXCR4 (15–17). We therefore specu-
lated that the chemotactic molecule released by retinal cells in 
the presence of HMGB1 was CXCL12. To test this, we first 
measured CXCL12 levels in the supernatants of retinal cells 
cultured alone or cocultured with IRBP-specific T cells in the 
presence or absence of anti-HMGB1 Ab, glycyrrhizin, or anti-
RAGE Ab. As shown in Figure 3A, high levels of CXCL12 were 
found in supernatants from cocultures of IRBP-specific T cells 
and retinal explants, whereas only low amounts were detected 
in cultures of retinal explants or IRBP-specific T cells alone or 
in cocultures of retinal explants and IRBP-specific T cells in 
the presence of anti-HMGB1 Ab, glycyrrhizin, or anti-RAGE 
Ab, showing that both cell types were required and that these 
HMGB1 inhibitors either inhibited or reduced CXCL12 produc-
tion by cocultured retinal cells. The in vitro increase in CXCL12 
levels in cocultures of retinal explants and activated IRBP-specific 
T cells was confirmed in  vivo in a study in which the transfer 
of IRBP-specific T cells to naïve mice was accompanied by AC 
injection of either anti-HMGB1 Ab or control Ig into each eye, 
then CXCL12 levels in the intraocular fluid were measured the 
next day. As shown in Figure 3B, high CXCL12 level was seen 
in mice that received IRBP-specific T cells and control Ig, but 
not anti-HMGB1 Ab.
Moreover, neutralization of CXCL12 in the coculture super-
natants by anti-CXCL12 Ab (Figure  4A) or prior blockade of 
CXCR4, the CXCL12 receptor, on the responder splenocytes 
using anti-CXCR4 Ab (Figure 4B) inhibited induction of sple-
nocyte migration by coculture supernatants.
As shown by flow cytometry in Figures  4C–E, coculture 
supernatants from IRBP-specific T cells and retinal explants 
were effective in attracting both CD3+ T cells (Figure 4C) and 
CD11b+ macrophages (Figure 4E), and this effect was blocked 
by the presence of anti-HMGB1 Ab (anti-H) during the coculture 
of CXCL12 release or by addition of anti-CXCL12 Ab (anti-C) to 
the coculture supernatants. Coculture supernatants from IRBP-
specific T cells and retinal explants were not effective in attracting 
Gr-1-positive granulocytes (Figure 4D).
teaU Was attenuated by Blockade of 
cXcr4 Using aMD3100
We then examined the role of HMGB1/CXCL12 in vivo in tEAU 
by comparing severity in mice with and without treatment with 
the CXCR4 inhibitor, AMD3100. B6 mice were implanted 
with osmotic minipumps releasing AMD3100 at a rate of 
357 μg/day for 14  days (see Materials and Methods), a treat-
ment regime used in a study in which AMD3100 successfully 
inhibited induction of collagen-induced arthritis in mice (14). 
Two groups of control mice were included, one implanted with 
pumps containing PBS (PBS pump) and one with no implant 
(Ctrl). One day later, all mice were injected with IRBP-specific 
FigUre 3 | high mobility group box 1 (hMgB1) induces retinal cells to secrete cXcl12. (a) Medium or the supernatant from the T cells or retinal explants 
or the supernatant from the cocultures alone or with addition of anti-HMGB1 Ab, glycyrrhizin, or anti-receptor for advanced glycation end products (RAGE) Ab at the 
same doses as Figure 1B at the beginning of the coculture was assayed for CXCL12 by ELISA. **p < 0.01 compared to medium alone, #p < 0.05 and  ##p < 0.01 
compared to the coculture of retinal explants and IRBP-specific T cells in one-way ANOVA. (B) Naïve B6 mice were left untreated or were adoptively transferred with 
activated IRBP1–20-specific T cells (5 × 106 cells/mouse) and 1 µg of either anti-HMGB1 Ab or control Ig was injected into the anterior chamber of each eye. Next 
day, the intraocular fluid was collected and CXCL12 levels measured. The data are the mean ± SD for eight eyes per group. *p < 0.05 compared to the anti-HMGB1 
Ab-treated eye in one-way ANOVA.
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T cells to induce tEAU, then were examined for clinical signs 
of intraocular inflammation. Compared with either set of 
controls, the AMD3100-treated mice developed much milder 
ocular inflammation, as determined by the clinical score 
(Figure 5A). Histological evaluation on day 15 post-transfer of 
the control group and the AMD3100 pump group showed a well 
preserved retinal structure and minimal vitreous infiltrate in the 
AMD3100-treated mice (Figure 5B).
To determine which leukocyte subsets were dominant in 
tEAU and blocked by AMD3100, we analyzed eye-infiltrating 
cells in control- and AMD3100-treated mice on day 8 after 
disease induction by staining pooled single eye cells from each 
group with a panel of antibodies specific for different leuko-
cytes and flow cytometric analysis. As shown in Figures 5C,D, 
AMD3100-treated mice showed a profound reduction in infil-
trating cells. The percentage of αβ T cells dropped from 23.7% 
in the disease controls to 8.4% in mice treated with AMD3100, 
and the percentage of CD11b+Gr-1− monocytes/macrophages 
decreased from 8.4 to 2%. In addition, the percentage of CD11b+ 
Gr-1+ neutrophils was dramatically reduced (11 versus 1.3%) 
(Figure 5C). Moreover, the absolute number of infiltrating cells 
in each eye of AMD3100-treated mice was significantly reduced 
compared to the untreated control eye (Figure 5D). At the day 
8 post-T cell transfer, there were not many infiltrating CD11C+ 
dendritic cells and CD19+ B cells detected in both control and 
treated eyes.
Furthermore, IRBP-specific responses of T cells were sig-
nificantly reduced after treatment with AMD3100. Significant 
lower IRBP-specific T cell proliferation (Figure 6A) and IFN-γ 
and IL-17 release (Figure  6B) in response to stimulation with 
IRBP1–20 were seen with T cells from mice treated with AMD3100. 
However, no significant difference in IL-10 release was seen 
between AMD3100-treated and control mice, as we previously 
reported using anti-HMGB1Ab injection (8). To examine the 
reduced proliferation of lymphocytes a direct effect of CXCR4 
inhibition or an indirect effect on antigen-presenting cells, we 
performed cross tests in which T cell proliferation was measured 
using all four combinations of responder T cells and APCs from 
IRBP1–20-specific T cell transferred and AMD3100-treated or 
disease control mice. T cells from AMD3100-treated mice did 
not respond to increasing doses of IRBP1–20 Ag in the presence 
of APCs from either AMD3100-treated or disease control mice 
(Figure 6C), whereas T cells from control mice reacted well in the 
presence of APCs from control mice, but not AMD3100-treated 
mice (Figure 6D), indicating that dysfunction of both T cells and 
APCs contributed to the T cell hyporesponsiveness in AMD3100-
treated mice.
aMD3100 inhibits the increase in cXcl12 
and cXcr4 expression in the eye in teaU
Having demonstrated CXCL12 release by retinal cells after 
stimulation with HMGB1 or activated IRBP-specific T cells 
FigUre 4 | cXcl12 is the high mobility group box 1 (hMgB1)-induced molecule that attracts T cells. (a) Chemotactic index of medium or the 
supernatant from the T cells or retinal explants or the supernatant from the cocultures either alone or with addition of anti-CXCL12 Ab (5 µg/ml) at the end of the 
coculture. (B) Splenocytes were incubated with or without anti-CXCR4 Ab (50 µg/ml) for 30 min, then were washed and used in the migration assay as in panel 
(a). **p < 0.01 compared to medium alone; and ##p < 0.01 compared to the coculture supernatants of retinal explants and interphotoreceptor retinoid-binding 
protein-specific T cells, in one-way ANOVA. (c–e) Medium or the supernatant from the T cells or retinal explants or the supernatant from cocultures in the 
presence or absence of 1 µg/ml of anti-HMGB1 (anti-H) for 6 h or supernatant from cocultures to which anti-CXCL12 Ab (anti-C; 5 µg/ml) was added after 
coculture was used in the migration assay and the cells that migrated into the lower chamber were stained with anti-CD3 Ab (c), Ly6G Ab (D), or CD11b Ab  
(e) and analyzed by flow cytometry. **p < 0.01 compared to medium alone in one-way ANOVA.
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in  vitro (Figure  3), we examined in  vivo CXCL12 expression 
in naïve mice and in mice on day 15 after transfer of IRBP-
specific T cells with or without AMD3100 treatment. As shown 
in Figure 7A (left), immunochemical staining for CXCL12 (red 
stain, first row, center panel) showed that CXCL12 was consti-
tutively expressed on the retina, especially in the ganglion cell 
layer (GCL), inner plexiform layer (IPL), and outer plexiform 
layer (OPL). At the peak of disease (d15 post-T cell transfer; 
middle row), the retina became thinner and CXCL12 expres-
sion was increased in the neuroretina in all regions from the 
inner nuclear layer to the outer boundary of the outer nuclear 
layer. However, tEAU mice treated with AMD3100 (bottom 
row) showed similar CXCL12 expression to naïve mice (first 
row). Staining for astroglial cells using the marker GS (green 
stain) showed that not many GS cells expressed CXCL12 in 
naïve mice (first row, right panel), while during inflammation, 
more GS cells expressed CXCL12 (indicated by arrows, middle 
row, right panel), which was markedly reduced by AMD3100 
treatment (bottom row, right panel). Our results suggest that 
CXCL12 may play a role in the maintenance of retinal cells in 
specific layers in the adult retina.
We also examined expression of the specific CXCL12 recep-
tor, CXCR4, in the eye before, or after, 15 days of IRBP-specific 
T cell transfer with or without AMD3100 treatment. As seen in 
Figure 7B, no CXCR4 signal (red stain) was seen before tEAU 
induction (first row, center panel) indicating no endogenous 
expression of CXCR4 in the eye of naïve mice. However, CXCR4 
was detected in the infiltrating cells at the peak of disease (mid-
dle row, center panel) and significantly reduced by AMD3100 
treatment (bottom row, center panel). Staining for ionized 
calcium-binding molecule 1 (IBa1-1), a marker for macrophages/
microglia, was markedly increased at the peak of tEAU (green, 
middle row, left panel) and some Iba-1-expressing cells also 
expressed CXCR4 (indicated by arrows, middle row, right panel), 
and both effects were abolished in the AMD3100-treated mice 
(bottom row).
FigUre 5 | The cXcr4 inhibitor aMD3100 significantly inhibits teaU. Groups of mice were implanted with pumps filled with 5 mg of AMD3100 in 90 µl of 
PBS (AMD3100 pump) or PBS alone (PBS pump) 1 day before interphotoreceptor retinoid-binding protein (IRBP)-specific T cell transfer as described in Section 
“Materials and Methods” and examined weekly for clinical score (a) or on day 15 for (B). A group of mice was left untreated as positive controls (Ctrl). (a) The 
mean clinical score for all three groups and (B) the pathological score for the indicated groups (n = 12 mice) presented as the mean ± SE. Hematoxylin and eosin; 
original magnification, ×100. *p < 0.05 and **p < 0.01 compared to the Ctrl group using Mann–Whitney U test. (c) Identification of infiltrating leukocytes in the eye 
of day 8 post-IRBP1–20-specific T cell-injected mice treated with pumps containing AMD3100 or PBS (Ctrl group). A suspension of single ocular cells for each 
group was pooled (total five mice in control group, and four in treated group), stained with the indicated fluorescein isothiocyanate- and phycoerythrin-conjugated 
antibodies and analyzed by flow cytometry. The percentage of positive cells is indicated. (D) Summary of infiltrative leukocyte subsets, from each eye is shown. 
Cells recovered from eyes of each group were counted after trypan blue staining. The number of cells was calculated based on the percentage of subsets as 
determined by flow cytometry.
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DiscUssiOn
We have previously reported that HMGB1 is detected in culture 
supernatants as early as 2 h of coculture of retinal explants and 
activated IRBP-specific T cells and at 1 day after adoptive transfer 
of activated IRBP-specific T cells, and blockade of HMGB1 using 
antagonists reduces ocular inflammation and suppresses uveito-
genic T cell function (8, 9). However, how HMGB1 is involved in 
the pathogenesis of effector phase of uveitis is not clear.
It was recently demonstrated that HMGB1 is an enhancer of 
the activity of CXCL12 in stimulating the migration of mouse 
embryonic fibroblasts (15, 16). Our study further supports this 
and explores the synergistic roles of HMGB1 and CXCL12 in 
the infiltration of inflammatory cells at a very early stage of 
intraocular inflammation induced by uveitogenic autoreactive 
T cells. Our results in Figures 1 and 3 show that interaction of 
uveitogenic T cells with retinal cells initiated release of HMGB1 
and CXCL12 by retinal cells. CXCL12 release was dependent 
on HMGB1, since CXCL12 was not released from retinal cells 
in the presence of an anti-HMGB1 Ab (Figure 3). This process 
is very important for the subsequent role of inflammatory 
migration. Once the complex forms, the migration-stimulating 
activity of the supernatant was not affected by neutralization 
of HMGB1 by anti-HMGB1 Ab or glycyrrhizin (Figure  1B), 
a glycoconjugated triterpene produced by the licorice plant 
Glycyrrhiza glabra, which has been reported to inhibit the 
chemoattractant and mitogenic activities of HMGB1 on 3T3 
fibroblasts and binds to both HMG box domains (BoxA and 
BoxB) (18). We previously showed that injection of mice with 
HMGB1 antagonists on the same day as IRBP-specific T cell 
transfer inhibits uveitogenic T cell-induced intraocular inflam-
mation, but not when given later, indicating that HMGB1-
induced CXCL12 release might be an early event initiated by 
infiltrating effector T cells (8).
It is not known how these two molecules are structurally 
associated. Nuclear magnetic resonance chemical-shift mapping 
indicates contacts between CXCL12 and full-length HMGB1 
and its individual HMG boxes (17). HMGB1 binds to CXCL12 
monomers or promote binding of CXCL12 to CXCR4 by fixing 
the N-terminal domain of CXCL12 in the best conformation for 
triggering CXCR4 signaling (16). Fluorescence resonance energy 
transfer studies with tagged CXCR4 have indicated that the 
conformation of CXCR4 dimers interacting with the HMGB1/
CXCL12 heterocomplex is different from the conformation of 
those interacting with CXCL12 alone (17).
Receptor for advanced glycation end products has been 
shown to be the receptor responsible for HMGB1-induced 
migration (19). Our study showed that RAGE was required 
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for HMGB1-induced CXCL12 release from retinal cells and 
probably for the formation of the HMGB1/CXCL12 complex, 
but not for inflammatory cell migration per  se, since HMGB1-
induced CXCL12 release was inhibited by anti-RAGE mAb 
(Figure  1C), whereas HMGB1/CXCL12-induced migration of 
splenocytes was not (Figure  1B). The reason why a previous 
study found that HMGB1-induced chemotaxis of rat smooth 
muscle cells (SMCs) was inhibited not only by anti-HMGB1 
Abs but also by anti-RAGE Abs (20), might be that anti-RAGE 
Abs inhibit HMGB1-induced CXCL12 release from SMCs. Our 
results are also compatible with those reported by Schiraldi et al. 
(17), who showed that, in vitro, CXCL12 expression and release 
were increased in HMGB1-stimulated mouse fibroblasts from 
wild-type B6 mice, but not from RAGE-deficient (RAGE−/−) 
mice, whereas migration of bone marrow cells induced by a 
combination of HMGB1 and CXCL12 was similar in both sets 
of mice, while, in vivo, absence of RAGE in C57BL/6 mice did 
not prevent, but actually promoted, recruitment of monocytes 
into the injured muscle, excluding the possibility that inflamma-
tory cells were recruited through RAGE signaling. They argued 
that the role of RAGE in cell migration is to trigger CXCL12 
transcription (21) so that CXCL12 production is increased and 
sustained over time and that RAGE is no longer needed when 
sufficient CXCL12 is produced or present.
We found that CXCL12 was constitutively expressed in 
the GCL, IPL, and OPL of the mouse retina (Figure  7A). 
However, its role in the normal retina is not known. Since it is 
chemotactic for CXCR4 positive immune cells such as T cells 
and monocytes, it might be actively involved in intraocular 
inflammation. CXCR4 has been implicated in ocular leukocyte 
trafficking in an ovalbumin-induced acute uveitis model in 
DO11.10 mice with CD4+ T cells genetically engineered to react 
with ovalbumin (22). In addition, it might promote endothelial 
cell migration and enhance angiogenesis, the latter effect being 
supported by reports that CXCL12 promotes angiogenesis in 
the diabetic retina in rats (23) and oxygen-induced retinopathy 
in mice (24).
Most adoptively transferred disease-inducing T cells require 
“licensing for pathogenicity” in the lung and other organs in 
order to induce disease in target organs (23, 25)—“a hub-and-
spoke pattern” (24). Both “licensing for pathogenicity” and 
HMGB1 production might take place during the induction of 
the effector phase of EAU. Release of intraocular HMGB1 and 
CXCL12 on day 1 after cell transfer shown in our previous 
FigUre 6 | reduced responses of interphotoreceptor retinoid-binding protein (irBP)-specific T cells in aMD3100-treated mice. (a,B) T cells from 
tEAU mice treated with AMD3100 or the Ctrl group were collected on day 15 after T cell transfer and cultured with irradiated antigen-presenting cells (APCs) and 
increasing doses of IRBP1–20, then proliferation of responding T cells (a), and levels of IFN-γ, IL-17, and IL-10 (B) released into the culture supernatants were 
measured. (c,D) Responder T cells prepared at day 8 post-IRBP1–20-specific T cell-injected mice treated with AMD3100 [(c), five mice] or control groups [(D), four 
mice] were incubated with increasing doses of IRBP1–20 in the presence of irradiated splenic APCs from either AMD3100- or control-treated mice and their 
proliferation measured. *p < 0.05 and **p < 0.01 compared to the Crtl group in Student’s t-test.
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study (8) might attract “licensed” pathogenic T cells to the eye, 
and the later HMGB1 increase might be related to the involve-
ment of these T cells and the damage they invoke in the retina. 
AMD3100 treatment might block the migration of licensed 
pathogenic T cells to the eye, leading to T cell apoptosis due to 
lack of reactivation in the target organ. Moreover, as shown in this 
study, AMD3100 treatment reduced the subsequent intraocular 
cascading and retina damage (Figures  5 and 7), resulting in 
a reduced frequency of naïve T cells activated by uveitogenic 
antigens released from the damaged retina, as demonstrated by 
low proliferative and cytokine production responses in vitro by 
IRBP-specific T cells from AMD3100-treated mice (Figure  6). 
Results in Figures  6C,D showed that AMD3100-treated APCs 
could not present antigens to activate T cells from controlled 
mice, indicating that low responsiveness of specific T cells is 
partially due to the reduced antigen-presenting functions of 
APCs such as monocytes/macrophages. Blockade of CXCR4 on 
APCs probably reduces the expression of positive costimulatory 
molecules, which is an interesting observation and needs to be 
further investigated.
In summary, our study demonstrates synergistic roles of 
HMGB1 and CXCL12 in the infiltration of inflammatory cells at 
a very early stage of intraocular inflammation induced by uveito-
genic autoreactive T cells. In our animal model, early blockade of 
released HMGB1 decreases CXCL12-induced leukocyte migra-
tion into the eye and subsequent intraocular inflammation and 
photoreceptor cell damage (Figure 8).
eThics sTaTeMenT
This study was carried out in accordance with the recommen-
dations of University of Louisville. Institutional approval was 
obtained and institutional guidelines regarding animal experi-
mentation were followed.
FigUre 7 | cXcl12 and cXcr4 expression in retinas. Expression of CXCL12 (a) and CXCR4 (B) was examined on paraffin-embedded sections of retina from 
naïve mice and from mice on day 15 after interphotoreceptor retinoid-binding protein-specific T cell transfer treated with or without AMD3100 by staining with 
phycoerythrin-conjugated anti-CXCL12 Ab [red in panel (a)] or anti-CXCR4 Ab [red in panel (B)] and fluorescein isothiocyanate-conjugated anti-glutamine 
synthetase (GS) Ab [green in panel (a)] or anti-Iba-1 Ab [green in panel (B)]. The right columns show the fused image. Cell nuclei are stained blue with DAPI.
FigUre 8 | Brief summary of the mechanism of hMgB1-cXcl12 in the pathogenesis of effector phase of eaU.
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